Key facts
- Notable investors include Bozhou Innovation Venture Capital, Ruikang Pharmaceutical.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Longhuikang
- ·The full record, as it builds
Funding rounds
No funding rounds for Longhuikang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Longhuikang
Manufacturer of processed botanical formulations designed for therapeutic and clinical use. The company offers automated slicing and drying systems, multi-format containment and storage infrastructure, and integrated quality control laboratories equipped with chromatographic and spectrometric instruments, serving pharmaceutical distributors and healthcare institutions to access standardized herbal components with verified purity, traceability, and scalable supply chain efficiency.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Bozhou, China
- Founded
- 2020
- Ownership
- Acquired/Merged (Operating Subsidiary)
Longhuikang doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Longhuikang shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Longhuikang in its N-PORT filings yet. We sweep new filings monthly.